Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364314 | 0.88 | NPC1 (0.43) | NPC1RAB9AKIF11GAATAAR1 | |
| SCHEMBL4364972 | 0.86 | PTPN1 (0.38) | KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL4359150 | 0.83 | NPC1 (0.45) | NPC1RAB9AKIF11GAATAAR1 | |
| SCHEMBL10309879 | 0.78 | KIF11 (0.45) | NPC1RAB9AKIF11POLBSMN1; SMN2 | |
| SCHEMBL6302955 | 0.78 | KIF11 (0.45) | NPC1RAB9AKIF11POLBSMN1; SMN2 | |
| SCHEMBL8053146 | 0.78 | KIF11 (0.45) | NPC1RAB9AKIF11POLBSMN1; SMN2 | |
| SCHEMBL9439820 | 0.73 | KIF11 (0.47) | KIF11POLBSIGMAR1SMN1; SMN2KDM4E | |
| SCHEMBL888258 | 0.73 | KIF11 (0.44) | NPC1RAB9AKIF11POLBSMN1; SMN2 | |
| SCHEMBL4374351 | 0.72 | CASR (0.52) | GAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL29142567 | 0.72 | KIF11 (0.39) | NPC1RAB9AKIF11POLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908829-B1 | OLIGONUCLEOTIDE PROBE | NAT INST OF ADVANCED IND SCIEN (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-7491857-B2 | Oligonucleotide probe | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080227968-A1 | Oligonucleotide Probe | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1908829-A1 | OLIGONUCLEOTIDE PROBE | National Institute of Advanced Industrial Science and Technology (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227968-A1 | Oligonucleotide Probe | APEX1, RNGTT, RNASEH1 | NPC1 3238/4885RAB9A 4788/4885KIF11 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.